Premium Content Regulatory alerts
Entyvio® accepted for moderately to severely active Crohn's disease (restricted)
Restricted to patients who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist.
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via